ReviewClinical & translational immunology2018
Regulatory T cells in renal disease.
Review in Clinical & translational immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- Article
- Novel Molecular Signatures of Peripheral Regulatory T Cells in Kidney Disease Associated with Type 1 Diabetes.Kidney360 · 2026Article
- Unveiling the impact of bisphenol a exposure on gene expression and immune response in diabetic nephropathy through integrative toxicogenomics and molecular dynamics approaches.Diabetology & metabolic syndrome · 2025Article
- Association between immune cells and membranous nephropathy: a two-sample Mendelian randomization study.Archives of medical science : AMS · 2025Article
- Immunomodulation Driven by Theranova Filter during a Single HD Session.Journal of clinical medicine · 2024Article
- Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.European heart journal · 2023Article
- The role of regulatory T cells in the pathogenesis of acute kidney injury.Journal of cellular and molecular medicine · 2023Article
- The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease.Frontiers in physiology · 2023Review
- Identification of Unique Genetic Biomarkers of Various Subtypes of Glomerulonephritis Using Machine Learning and Deep Learning.Biomolecules · 2022Article
- A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives.Frontiers in immunology · 2022Review
- M2c Macrophages Protect Mice from Adriamycin-Induced Nephropathy by Upregulating CD62L in Tregs.Mediators of inflammation · 2022Article
- Probiotics partially attenuate the severity of acute kidney injury through an immunomodulatory effect.Kidney research and clinical practice · 2021Article
- Role of T-lymphocytes in Kidney Disease.Cureus · 2021Article
- The Roles of Kidney-Resident ILC2 in Renal Inflammation and Fibrosis.Frontiers in immunology · 2021Review
- Microbiome, Immunosenescence, and Chronic Kidney Disease.Frontiers in medicine · 2021Review
- Mesenchymal Stem Cell Protects Injured Renal Tubular Epithelial Cells by Regulating mTOR-Mediated Th17/Treg Axis.Frontiers in immunology · 2021Review
- Amphiregulin Aggravates GlomerulonephritisJournal of the American Society of Nephrology : JASN · 2020Article
- Immune cell landscaping reveals a protective role for regulatory T cells during kidney injury and fibrosis.JCI insight · 2020Article
- Focus on the Gut-Kidney Axis in Health and Disease.Frontiers in medicine · 2020Review
- IL-10 from dendritic cells but not from T regulatory cells protects against cisplatin-induced nephrotoxicity.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kidney is vulnerable to injury, both acute and chronic from a variety of immune and metabolic insults, all of which at least to some degree involve inflammation. Regulatory T cells modulate systemic autoimmune and allogenic responses in glomerulonephritis and transplantation. Intrarenal regulatory T cells (Tregs), including those recruited to the kidney, have suppressive effects on both adaptive and innate immune cells, and probably also intrinsic kidney cells. Evidence from autoimmune glomerulonephritis implicates antigen-specific Tregs in HLA-mediated dominant protection, while in several human renal diseases Tregs are abnormal in number or phenotype. Experimentally, Tregs can protect the kidney from injury in a variety of renal diseases. Mechanisms of Treg recruitment to the kidney include via the chemokine receptors CCR6 and CXCR3 and potentially, at least in innate injury TLR9. The effects of Tregs may be context dependent, with evidence for roles for immunoregulatory roles both for endogenous Tbet-expressing Tregs and STAT-3-expressing Tregs in experimental glomerulonephritis. Most experimental work and some of the ongoing human trials in renal transplantation have focussed on unfractionated thymically derived Tregs (tTregs). However, induced Tregs (iTregs), type 1 regulatory T (Tr1) cells and in particular antigen-specific Tregs also have therapeutic potential not only in renal transplantation, but also in other kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.